title: Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.
abstract: MICs and biofilm inhibitory concentrations (BICs) were measured for 68 cystic fibrosis (CF) Achromobacter isolates for amikacin, aztreonam, colistin, levofloxacin, and tobramycin. With the exception of colistin and levofloxacin, the remaining antibiotics had MIC90s, BICs at which 50% of the isolates were susceptible (BIC50s), and BICs at which 90% of the isolates were susceptible (BIC90s) equal to or above the highest concentrations tested. In a biofilm model, tobramycin was able to significantly increase killing of bacterial cells compared to controls, for intermediate-resistant strains only, at concentrations of 1,000 and 2,000 μg/ml.
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
authors.forename: Sean K
authors.initials: SK
authors.lastname: Tom
authors.affiliation: Division of Microbiology, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
authors.forename: Yvonne C W
authors.initials: YC
authors.lastname: Yau
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
authors.forename: Trevor
authors.initials: T
authors.lastname: Beaudoin
authors.affiliation: Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
authors.forename: John J
authors.initials: JJ
authors.lastname: LiPuma
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada valerie.waters@sickkids.ca.
authors.forename: Valerie
authors.initials: V
authors.lastname: Waters
mesh_terms: D042402:Achromobacter / Q000187:drug effects* / Q000302:isolation & purification / Q000502:physiology; D000583:Amikacin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam / Q000494:pharmacology; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D003091:Colistin / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000150:complications / Q000382:microbiology*; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000382:microbiology*; D006801:Humans; D064704:Levofloxacin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010933:Plankton / Q000187:drug effects / Q000254:growth & development; D014031:Tobramycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D000583:Amikacin; D001398:Aztreonam; D014031:Tobramycin; D003091:Colistin